21 studies found for:    melanoma metastatic liver | Open Studies
Show Display Options
Rank Status Study
1 Unknown  TACE With Drug Eluting Beads Loaded With Doxorubicin in Liver Metastases From Melanoma Patients
Condition: Stage IV Melanoma Patients With Unresectable Liver Metastases
Intervention: Device: TACE using Drug Eluting Beads loaded with Doxorubicin
2 Recruiting RADVAX: A Stratified Phase I/II Dose Escalation Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Metastatic Melanoma
Condition: Metastatic Melanoma
Interventions: Drug: Ipilimumab;   Radiation: Stereotactic Body Radiation Therapy
3 Recruiting Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma
Conditions: Liver Metastases;   Lung Metastases;   Recurrent Melanoma;   Stage IV Melanoma;   Tumors Metastatic to Brain
Interventions: Biological: ipilimumab;   Radiation: stereotactic radiosurgery;   Other: laboratory biomarker analysis
4 Recruiting An Observational Safety Study in Zelboraf (Vemurafenib)-Treated Patients With BRAF-V600 Mutation-Positive Unresectable or Metastatic Melanoma (ZeSS)
Condition: Malignant Melanoma
Intervention:
5 Unknown  Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer
Condition: Cancer
Interventions: Drug: cyclophosphamide;   Other: laboratory biomarker analysis;   Procedure: biopsy;   Procedure: cryosurgery
6 Recruiting Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery
Conditions: Male Breast Cancer;   Recurrent Melanoma;   Stage IV Breast Cancer;   Stage IV Melanoma;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Unspecified Adult Solid Tumor, Protocol Specific;   Hepatocellular Carcinoma
Interventions: Drug: propranolol hydrochloride;   Other: Correlative Studies
7 Recruiting Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Ependymoma;   Adult Anaplastic Oligodendroglioma;   Adult Brain Stem Glioma;   Adult Ependymoblastoma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Adult Nasal Type Extranodal NK/T-Cell Lymphoma;   Adult Pineal Gland Astrocytoma;   Adult Solid Neoplasm;   AIDS Related Immunoblastic Lymphoma;   AIDS-Related Burkitt Lymphoma;   AIDS-Related Diffuse Large Cell Lymphoma;   AIDS-Related Diffuse Mixed Cell Lymphoma;   AIDS-Related Diffuse Small Cleaved Cell Lymphoma;   AIDS-Related Hodgkin Lymphoma;   AIDS-Related Lymphoblastic Lymphoma;   AIDS-Related Lymphoma;   AIDS-Related Primary Central Nervous System Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-Cell Lymphoma;   Cutaneous B-Cell Non-Hodgkin Lymphoma;   Extensive Stage Small Cell Lung Carcinoma;   Extra-Adrenal Paraganglioma;   Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   Gastrin-Producing Neuroendocrine Tumor;   Hepatic Complication;   Hepatosplenic T-Cell Lymphoma;   Intraocular Lymphoma;   Lung Carcinoid Tumor;   Lymphomatous Involvement of Non-Cutaneous Extranodal Site;   Male Breast Carcinoma;   Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Metastatic Adrenal Gland Pheochromocytoma;   Metastatic Gastrointestinal Neuroendocrine Tumor G1;   Nasal Cavity Inverted Papilloma;   Nodal Marginal Zone Lymphoma;   Olfactory Neuroblastoma;   Pancreatic Glucagonoma;   Pancreatic Insulinoma;   Pancreatic Polypeptide Tumor;   Poorly Differentiated Thyroid Gland Carcinoma;   Recurrent Adrenal Gland Pheochromocytoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Brain Neoplasm;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Adult T-Cell Leukemia/Lymphoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Colon Carcinoma;   Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma;   Recurrent Gastrointestinal Neuroendocrine Tumor G1;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Hypopharyngeal Squamous Cell Carcinoma;   Recurrent Inverted Schneiderian Papilloma;   Recurrent Laryngeal Squamous Cell Carcinoma;   Recurrent Laryngeal Verrucous Carcinoma;   Recurrent Lip and Oral Cavity Squamous Cell Carcinoma;   Recurrent Lip Basal Cell Carcinoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Melanoma;   Recurrent Merkel Cell Carcinoma;   Recurrent Metastatic Squamous Cell Carcinoma to the Neck With Occult Primary;   Recurrent Mycosis Fungoides and Sezary Syndrome;   Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Recurrent Nasal Type NK/T-Cell Lymphoma;   Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma;   Recurrent Nasopharyngeal Undifferentiated Carcinoma;   Recurrent Non-Small Cell Lung Carcinoma;   Recurrent Olfactory Neuroblastoma;   Recurrent Oral Cavity Adenoid Cystic Carcinoma;   Recurrent Oral Cavity Mucoepidermoid Carcinoma;   Recurrent Oral Cavity Verrucous Carcinoma;   Recurrent Oropharyngeal Squamous Cell Carcinoma;   Recurrent Oropharyngeal Undifferentiated Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Pancreatic Neuroendocrine Carcinoma;   Recurrent Prostate Carcinoma;   Recurrent Rectal Carcinoma;   Recurrent Renal Cell Carcinoma;   Recurrent Salivary Gland Carcinoma;   Recurrent Small Cell Lung Carcinoma;   Recurrent Small Lymphocytic Lymphoma;   Recurrent Thyroid Gland Carcinoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Regional Adrenal Gland Pheochromocytoma;   Regional Gastrointestinal Neuroendocrine Tumor G1;   Small Intestinal Lymphoma;   Somatostatin-Producing Neuroendocrine Tumor;   Splenic Marginal Zone Lymphoma;   Squamous Cell Carcinoma Metastatic to the Neck With Occult Primary;   Stage III Adult Soft Tissue Sarcoma;   Stage III Bladder Cancer;   Stage III Hypopharyngeal Squamous Cell Carcinoma;   Stage III Laryngeal Squamous Cell Carcinoma;   Stage III Laryngeal Verrucous Carcinoma;   Stage III Lip and Oral Cavity Squamous Cell Carcinoma;   Stage III Lip Basal Cell Carcinoma;   Stage III Major Salivary Gland Carcinoma;   Stage III Merkel Cell Carcinoma;   Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage III Nasal Type NK/T-Cell Lymphoma;   Stage III Nasopharyngeal Keratinizing Squamous Cell Carcinoma;   Stage III Nasopharyngeal Undifferentiated Carcinoma;   Stage III Oral Cavity Adenoid Cystic Carcinoma;   Stage III Oral Cavity Mucoepidermoid Carcinoma;   Stage III Oral Cavity Verrucous Carcinoma;   Stage III Oropharyngeal Squamous Cell Carcinoma;   Stage III Oropharyngeal Undifferentiated Carcinoma;   Stage III Pancreatic Cancer;   Stage III Prostate Cancer;   Stage III Renal Cell Cancer;   Stage III Thyroid Gland Follicular Carcinoma;   Stage III Thyroid Gland Papillary Carcinoma;   Stage IIIA Breast Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIA Rectal Cancer;   Stage IIIA Skin Melanoma;   Stage IIIB Breast Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IIIB Rectal Cancer;   Stage IIIB Skin Melanoma;   Stage IIIC Breast Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Rectal Cancer;   Stage IIIC Skin Melanoma;   Stage IV Adult Soft Tissue Sarcoma;   Stage IV Bladder Cancer;   Stage IV Breast Cancer;   Stage IV Hypopharyngeal Squamous Cell Carcinoma;   Stage IV Merkel Cell Carcinoma;   Stage IV Nasal Type NK/T-Cell Lymphoma;   Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma;   Stage IV Nasopharyngeal Undifferentiated Carcinoma;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Pancreatic Cancer;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Stage IV Skin Melanoma;   Stage IVA Basal Cell Lip Carcinoma;   Stage IVA Colon Cancer;   Stage IVA Laryngeal Squamous Cell Carcinoma;   Stage IVA Laryngeal Verrucous Carcinoma;   Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVA Major Salivary Gland Carcinoma;   Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVA Oral Cavity Adenoid Cystic Carcinoma;   Stage IVA Oral Cavity Mucoepidermoid Carcinoma;   Stage IVA Oral Cavity Verrucous Carcinoma;   Stage IVA Oropharyngeal Squamous Cell Carcinoma;   Stage IVA Oropharyngeal Undifferentiated Carcinoma;   Stage IVA Rectal Cancer;   Stage IVA Thyroid Gland Follicular Carcinoma;   Stage IVA Thyroid Gland Papillary Carcinoma;   Stage IVB Basal Cell Lip Carcinoma;   Stage IVB Colon Cancer;   Stage IVB Laryngeal Squamous Cell Carcinoma;   Stage IVB Laryngeal Verrucous Carcinoma;   Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVB Major Salivary Gland Carcinoma;   Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVB Oral Cavity Adenoid Cystic Carcinoma;   Stage IVB Oral Cavity Mucoepidermoid Carcinoma;   Stage IVB Oral Cavity Verrucous Carcinoma;   Stage IVB Oropharyngeal Squamous Cell Carcinoma;   Stage IVB Oropharyngeal Undifferentiated Carcinoma;   Stage IVB Rectal Cancer;   Stage IVB Thyroid Gland Follicular Carcinoma;   Stage IVB Thyroid Gland Papillary Carcinoma;   Stage IVC Basal Cell Lip Carcinoma;   Stage IVC Laryngeal Squamous Cell Carcinoma;   Stage IVC Laryngeal Verrucous Carcinoma;   Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVC Major Salivary Gland Carcinoma;   Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVC Oral Cavity Adenoid Cystic Carcinoma;   Stage IVC Oral Cavity Mucoepidermoid Carcinoma;   Stage IVC Oral Cavity Verrucous Carcinoma;   Stage IVC Oropharyngeal Squamous Cell Carcinoma;   Stage IVC Oropharyngeal Undifferentiated Carcinoma;   Stage IVC Thyroid Gland Follicular Carcinoma;   Stage IVC Thyroid Gland Papillary Carcinoma;   T-Cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Thyroid Gland Medullary Carcinoma;   Thyroid Gland Undifferentiated (Anaplastic) Carcinoma;   Tongue Carcinoma;   Waldenstrom Macroglobulinemia
Interventions: Drug: Romidepsin;   Other: Pharmacological Study
8 Unknown  Melanoma Inhibitory Activity (MIA): A Serological Marker for Metastatic Uveal Melanoma
Conditions: Melanoma;   Radiotherapy;   Metastatic Disease
Intervention: Procedure: Treatment of metastatic disease
9 Recruiting Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome in Patients With Brain Tumors
Conditions: Primary Brain Tumors;   Metastatic Malignant Neoplasm to Brain
Intervention: Drug: 4-Demethyl-4-cholestryloxycarbonylpenclomedine
10 Not yet recruiting A Study Of PF-04518600 In Patients With Select Advanced Solid Tumors
Condition: Neoplasms
Intervention: Drug: PF-04518600
11 Recruiting Sorafenib and Radioembolization With Sir-Spheres® for the Treatment of Metastatic Ocular Melanoma
Condition: Ocular Melanoma
Interventions: Drug: Sorafenib;   Device: Radioembolization with SIR-Spheres® (Yttrium Microspheres)
12 Recruiting Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
Conditions: Adult Solid Neoplasm;   Bladder Carcinoma;   Breast Carcinoma;   Endometrial Carcinoma;   Esophageal Carcinoma;   Lung Carcinoma;   Malignant Head and Neck Neoplasm;   Melanoma;   Ovarian Neoplasm;   Renal Pelvis and Ureter Urothelial Carcinoma;   Testicular Lymphoma;   Ureter Carcinoma;   Urethral Carcinoma
Interventions: Drug: Veliparib;   Drug: Paclitaxel;   Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
13 Recruiting CC-486 (Oral Azacitidine) Bioequivalence Study in Patients With Solid Tumor or Hematologic Malignancies
Conditions: Hematological Neoplasms;   Non-Hodgkin's Lymphoma;   Hodgkin's Lymphoma;   Lymphoma;   Multiple Myeloma;   Acute Myeloid Leukemia;   Leukemia;   Myelodysplastic Syndromes;   Neoplasms;   Melanoma;   Breast Cancer;   Metastatic Breast Cancer;   Non-Small Cell Lung Cancer;   Small Cell Lung Cancer;   Renal Cell Carcinoma;   Glioblastoma Multiforme;   Osteosarcoma;   Sarcoma;   Thyroid Cancer;   Genitourinary
Interventions: Drug: CC-486;   Drug: Vidaza
14 Recruiting Safety and Efficacy Study of DCVax-Direct in Solid Tumors
Conditions: Locally Advanced Tumor;   Metastatic Solid Tissue Tumors;   Liver Cancer;   Colorectal Cancer;   Pancreatic Cancer;   Melanoma
Intervention: Biological: DCVax-Direct
15 Unknown  SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma
Condition: Malignant Melanoma
Interventions: Biological: SentoClone®;   Drug: Temodal® or Dacarbazine Medac®
16 Recruiting Collecting Solid Tumor Tissue to Identify New Treatments
Conditions: Gastrointestinal Cancer;   Liver Cancer;   Pancreatic Cancer;   Melanoma
Intervention:
17 Recruiting Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Oligodendroglioma;   Adult Glioblastoma;   Adult Soft Tissue Sarcoma;   Adult Solid Neoplasm;   Anaplastic Oligoastrocytoma;   Endometrial Serous Adenocarcinoma;   Estrogen Receptor Negative;   Estrogen Receptor Positive;   Hormone-Resistant Prostate Cancer;   Male Breast Carcinoma;   Metastatic Prostate Carcinoma;   Recurrent Adult Brain Neoplasm;   Recurrent Adult Hepatocellular Carcinoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Colon Carcinoma;   Recurrent Esophageal Carcinoma;   Recurrent Gastric Carcinoma;   Recurrent Lung Carcinoma;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Prostate Carcinoma;   Recurrent Rectal Carcinoma;   Recurrent Renal Cell Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Recurrent Uterine Corpus Sarcoma;   Resectable Hepatocellular Carcinoma;   Stage IA Breast Cancer;   Stage IA Ovarian Cancer;   Stage IA Uterine Corpus Cancer;   Stage IA Uterine Sarcoma;   Stage IB Breast Cancer;   Stage IB Ovarian Cancer;   Stage IB Uterine Corpus Cancer;   Stage IB Uterine Sarcoma;   Stage IC Ovarian Cancer;   Stage IC Uterine Sarcoma;   Stage II Uterine Corpus Cancer;   Stage IIA Breast Cancer;   Stage IIA Lung Carcinoma;   Stage IIA Ovarian Cancer;   Stage IIA Uterine Sarcoma;   Stage IIB Breast Cancer;   Stage IIB Esophageal Cancer;   Stage IIB Lung Carcinoma;   Stage IIB Ovarian Cancer;   Stage IIB Skin Melanoma;   Stage IIB Uterine Sarcoma;   Stage IIC Ovarian Cancer;   Stage IIC Skin Melanoma;   Stage IIIA Breast Cancer;   Stage IIIA Esophageal Cancer;   Stage IIIA Lung Carcinoma;   Stage IIIA Ovarian Cancer;   Stage IIIA Skin Melanoma;   Stage IIIA Uterine Corpus Cancer;   Stage IIIA Uterine Sarcoma;   Stage IIIB Breast Cancer;   Stage IIIB Esophageal Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Skin Melanoma;   Stage IIIB Uterine Corpus Cancer;   Stage IIIB Uterine Sarcoma;   Stage IIIC Breast Cancer;   Stage IIIC Esophageal Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Skin Melanoma;   Stage IIIC Uterine Corpus Cancer;   Stage IIIC Uterine Sarcoma;   Stage IV Bladder Urothelial Carcinoma;   Stage IV Esophageal Cancer;   Stage IV Ovarian Cancer;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Stage IV Skin Melanoma;   Stage IVA Uterine Corpus Cancer;   Stage IVA Uterine Sarcoma;   Stage IVB Uterine Corpus Cancer;   Stage IVB Uterine Sarcoma
Interventions: Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401;   Drug: Sirolimus;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
18 Recruiting Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Conditions: Metastatic Colorectal Cancer;   Metastatic Gastric Cancer;   Metastatic Pancreatic Cancer;   Metastatic Hepatocellular Carcinoma;   Metastatic Cholangiocarcinoma
Interventions: Biological: Young TIL;   Drug: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine
19 Unknown  Phase II Study With Immunotherapy With Dendritic Cells and Tumor Infiltrating Lymphocytes in Solid Tumors
Conditions: Renal Cell Carcinoma;   Melanoma;   Carcinoma, Hepatocellular
Intervention: Biological: immunotherapy with dendritic cells
20 Recruiting Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum
Conditions: Lung Cancer;   Esophageal Cancer;   Malignant Pleural Mesothelioma;   Sarcoma;   Thymic Carcinoma
Interventions: Biological: H1299 Lysate Vaccine;   Drug: Cyclophosphamide;   Drug: Celecoxib

   Previous Page Studies Shown (1-20) Next Page (21-21) Show next page of results    Last Page
Indicates status has not been verified in more than two years